NANOCURCUMIN SELECTIVELY ACTIVATES ENDOTHELIAL NITRIC OXIDE IN MIDDLE UTERINE ARTERY OF GOAT (CAPRA HIRCUS)

Objective: The present study is designed to investigate vasorelaxation mechanisms of Nanocurcumin in the middle uterine artery (MUA) of both non-pregnant (NP) and pregnant (P) Capra hircus (Ch). Methods: MUA rings were mounted in an automatic organ bath and the contractile response was recorded isometrically by highly sensitive force transducer connected to a power lab data acquisition system. Nanocurcumin (1 pM-100 µM) vasorelaxation response (NCVR) was elicited in PE-precontracted rings either in the absence or presence of different blockers. Results: The maximal vasorelaxation (R_max) to Nanocurcumin in phenylephrine-precontracted endothelium intact MUA rings of NP (40.36 ± 2.38%) and of P (44.09 ± 3.41%) was reduced to 22.93 ± 0.80% and 25.37 ± 2.2% in endothelium-denuded MUA rings of NP and P Ch. L-NAME, Indomethacin and L-NAME + Indomethacin inhibited NCVR by significantly decreasing the R_max to 17.65%, 28.42%, 17.95% in NP and to 27.34%, 39.06%, 24.50% in P Ch. The ODQ and carbenoxolone/18β Glycyrrhetinic acid did not inhibit the R_max of NCVR. Conclusion: Nanocurcumin potentially dilates the MUA of both NP and PCh. The endothelial L-NAME sensitive eNOS is activated by Nanocurcumin and it has the potential to increase blood flow to the uterus and fetus. Additionally, it could also be useful in the effective treatment of hypertensive disorders such as pre-eclampsia.